Safety and Efficacy of Combining Tagraxofusp with AZA or AZA+VEN in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. ASH 2021.

Poster

A Multicenter Phase 1/2 Trial of Tagraxofusp in Patients with Poor-Risk MF. ASH 2020.

Poster

Evaluation of Tagraxofusp(SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms. ASH 2019.

Poster

Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASH 2019.

Oral Presentation

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. ASH 2019.

Poster

CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp. ACR 2019.

Poster

Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. AACR 2012.

Abstract | Poster

A pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma. AACR 2012.

Abstract

Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. ASCO 2011.

Abstract